Interleukin-1beta triggers the expansion of circulating granulocytic myeloid-derived suppressor cell subset dependent on Erk1/2 activation

Immunobiology ◽  
2021 ◽  
pp. 152165
Author(s):  
Huifang Shi ◽  
Yan Qin ◽  
Yufeng Tian ◽  
Jiaan Wang ◽  
Yan Wang ◽  
...  
2010 ◽  
Vol 40 (12) ◽  
pp. 3347-3357 ◽  
Author(s):  
Moshe Elkabets ◽  
Vera S. G. Ribeiro ◽  
Charles A. Dinarello ◽  
Suzanne Ostrand-Rosenberg ◽  
James P. Di Santo ◽  
...  

Author(s):  
Tomohiro Takano ◽  
Takayuki Matsumura ◽  
Yu Adachi ◽  
Kazutaka Terahara ◽  
Saya Moriyama ◽  
...  

Abstract An expanded myeloid cell compartment is a hallmark of severe coronavirus disease 2019 (COVID-19). However, data regarding myeloid cell expansion have been collected in Europe, where the mortality rate by COVID-19 is greater than those in other regions including Japan. Thus, characteristics of COVID-19-induced myeloid cell subsets remain largely unknown in the regions with low mortality rates. Here, we analyzed cellular dynamics of myeloid-derived suppressor cell (MDSC) subsets and examined whether any of them correlate with disease severity and prognosis, using blood samples from Japanese COVID-19 patients. We observed that polymorphonuclear (PMN)-MDSCs, but not other MDSC subsets, transiently expanded in severe cases but not in mild or moderate cases. Contrary to previous studies in Europe, this subset selectively expanded in survivors of severe cases and subsided before discharge, but such transient expansion was not observed in non-survivors in Japanese cohort. Analysis of plasma cytokine/chemokine levels revealed positive correlation of PMN-MDSC frequencies with interleukin 8 (IL-8) levels prior to the cell expansion, indicating the involvement of IL-8 on recruitment of PMN-MDSCs to peripheral blood following the onset of severe COVID-19. Thus, our data indicates that transient expansion of the PMN-MDSC subset results in improved clinical outcome. Thus, this myeloid cell subset may be a predictor of prognosis in cases of severe COVID-19 in Japan.


2015 ◽  
Vol 4 (3) ◽  
pp. e995541 ◽  
Author(s):  
Yusuke Sato ◽  
Kanako Shimizu ◽  
Jun Shinga ◽  
Michihiro Hidaka ◽  
Fumio Kawano ◽  
...  

2016 ◽  
Vol 23 (9) ◽  
pp. 2346-2355 ◽  
Author(s):  
Yana G. Najjar ◽  
Patricia Rayman ◽  
Xuefei Jia ◽  
Paul G. Pavicic ◽  
Brian I. Rini ◽  
...  

2020 ◽  
Vol 10 ◽  
Author(s):  
Varun Sasidharan Nair ◽  
Reem Saleh ◽  
Salman M. Toor ◽  
Nehad M. Alajez ◽  
Eyad Elkord

2021 ◽  
Vol 15 ◽  
pp. 117955492110355
Author(s):  
Tianhang Li ◽  
Tianyao Liu ◽  
Wenjie Zhu ◽  
Shangxun Xie ◽  
Zihan Zhao ◽  
...  

Immune-checkpoint blockade (ICB) demonstrated inspiring effect and great promise in anti-cancer therapy. However, many obstacles, such as drug resistance and difficulty in patient selection, limited the efficacy of ICB therapy and awaited to be overcome. By timely identification and intervention of the key immune-suppressive promotors in the tumor microenvironment (TME), we may better understand the mechanisms of cancer immune-escape and use novel strategies to enhance the therapeutic effect of ICB. Myeloid-derived suppressor cell (MDSC) is recognized as a major immune suppressor in the TME. In this review, we summarized the roles MDSC played in the cancer context, focusing on its negative biologic functions in ICB therapy, discussed the strategies targeted on MDSC to optimize the diagnosis and therapy process of ICB and improve the efficacy of ICB therapy against malignancies.


Sign in / Sign up

Export Citation Format

Share Document